This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Bio-Reference Laboratories, Inc. Announces Record First Quarter Revenue, Earnings And Cash Flow From Operations

Marc D. Grodman, MD, CEO, commented: “The milder than normal weather conditions, particularly in the Northeast, have contributed to the strength of our Q1 results when compared to our prior year results. However, and more importantly, the overall success of all our business units has been the primary reason for our strong financial results. All of our business units have been contributing to the on-going, sustained growth of the Company. Our New York Metropolitan area growth has been significant; the sustained success of our Women’s Health program has been outstanding; and we have seen no abatement in the growth of our oncology business. GeneDx, our genetics laboratory has continued to develop new services and new products that have maintained its status as a premier commercial diagnostic genetic laboratory.”

Dr. Grodman further noted: “We look forward to the introduction of our new initiatives. OnkoMatch was introduced in January and has generated considerable interest in the oncology community. Our cornerstone pre-natal product will be introduced during the current second fiscal quarter, but already we have seen great interest in our pre-natal program. Our NextGen sequencing services continue to generate great interest not only in the genetics community, but in the entire clinical community. We grow by breaking the laboratory services market down into smaller, marketable segments, and we develop those units through better technology, disruptive reporting, focused marketing and dedicated service. The result is growth, as clearly demonstrated in the current first quarter financials.”

Dr. Grodman concluded, “We affirm our guidance for our current fiscal year as announced in our Q4FY11 earnings call. We remain focused on being the technology leader, the marketing leader as well as the service leader in a service-dominated industry. We grow because we are able to identify the needs of the clinical diagnostic market and provide solutions to the needs of the healthcare providers. We don’t buy business; we sell our vision. We are committed to the disruptive technology and reporting advancements that have been the hallmark of our sustained growth and remain dedicated to continuing that model as we move forward.“

2 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,086.63 -26.91 -0.16%
S&P 500 1,987.01 +3.48 0.18%
NASDAQ 4,473.6970 +17.6810 0.40%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs